WuXi Biologics (Cayman) Inc.
2269
Peringkat dalam Saham
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Harga Saham
$5.77
Kapitalisasi Pasar
$23.74B
Perubahan (1 hari)
-8.38%
Perubahan (1 tahun)
25.13%
Negara
CN
Perdagangan WuXi Biologics (Cayman) Inc. (2269)
Kategori
Healthcare
Laba untuk WuXi Biologics (Cayman) Inc. (2269)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari WuXi Biologics (Cayman) Inc., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk WuXi Biologics (Cayman) Inc. dari 2014 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2025 | $1.04B | 56.60% |
| 2024 | $662.33M | 12.33% |
| 2023 | $589.64M | -24.09% |
| 2022 | $776.72M | 23.63% |
| 2021 | $628.25M | 108.78% |
| 2020 | $300.91M | 85.98% |
| 2019 | $161.80M | 50.86% |
| 2018 | $107.25M | 129.77% |
| 2017 | $46.68M | 84.29% |
| 2016 | $25.33M | 151.48% |
| 2015 | $10.07M | 27.28% |
| 2014 | $7.91M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
